

THE LANCET

Global Health

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Ruhwald M, Hannay E, Sarin S, Kao K, Sen R, Chadha S. Considerations for simultaneous testing of COVID-19 and tuberculosis in high-burden countries. *Lancet Glob Health* 2022; published online Feb 2. [https://doi.org/10.1016/S2214-109X\(22\)00002-X](https://doi.org/10.1016/S2214-109X(22)00002-X).

	Considerations
Policy	
Screening tools	<p>Develop affordable screening tools that integrate TB and COVID-19 testing and/or registration for all persons with symptoms of TB.</p> <ul style="list-style-type: none"> • In particular, TB screening checklists and registers for triaging patients should include symptoms to cover COVID-19. • A screening algorithm for simultaneous testing should also be developed. • Consider whether innovations developed for screening COVID-19 (e.g. contact tracing apps, symptom screening apps) could be leveraged as part of simultaneous testing.
Management and coordination	<p>Coordinate the simultaneous testing response with all stakeholders to ensure the smooth roll out of simultaneous testing and optimization of resources. Key stakeholders include national TB and COVID-19 disease programmes, NGOs, laboratory services, pharmacy chains, and the private sector. Consider whether sample referral systems established for COVID-19 could be leveraged for TB.</p>
Policy guidance	<p>Ensure processes and resources are in place to regularly update policy and operational guidance for simultaneous testing as new information becomes available and if the COVID-19 situation in the setting changes.</p>
Priority populations	<p>Where resources are limited, testing should focus on populations at greater risk for both infections (e.g. newly diagnosed TB or COVID-19 patients with comorbidities, people with diabetes and older people).</p>
Reporting/disease surveillance	<p>Consider integrating disease surveillance for TB and COVID-19 to simplify and improve reporting for both diseases. For example, this could involve daily/weekly notification of TB cases along with COVID-19.</p>
Operational	
Expansion of testing services	<p>Plan for expanded testing services to operationalize simultaneous testing and catch-up testing for TB to mitigate previous disruptions to TB testing.</p> <ul style="list-style-type: none"> • Specific considerations will depend on the testing options deployed (e.g. multiplex testing, rapid point-of-care tests, chest X-rays), and may include relocation or procurement of additional instruments. • Recruitment and cross-training of staff will be required to enable staff to adequately support both the TB and COVID-19 programmes. • Consider expanding TB and COVID-19 testing to community/decentralized locations especially during periods of lockdown.
Simultaneous testing facilities	<p>Ensure that safe sputum collection sites are available at COVID-19 clinics and that PPE for safe collection of COVID-19 samples is available at TB clinics.</p>
Optimization of testing capacity	<p>Consider diagnostic network optimization approaches to optimize testing capacity in terms of placement of testing sites and instruments, and sample referral networks.</p>
Utilization of electronic data reporting/platforms	<ul style="list-style-type: none"> • Leverage electronic data reporting/platforms with inbuilt connectivity to streamline reporting of the testing approaches. • Update COVID-19 symptom screening materials to include differential diagnosis of TB and other respiratory diseases. • Use integrated surveillance tools for mapping TB and COVID-19 hotspots where feasible.

	<ul style="list-style-type: none"> Consider deployment of solutions like rapid test reader apps to allow accurate interpretation of rapid antigen test results with simultaneous transmission of results to the country database.
Contact tracing	Efforts should be made to integrate COVID-19 testing into TB contact testing checklists and registers, and vice versa . Resources may be needed to recruit additional community health workers and for cross-training of health workers for both TB and COVID-19 sample collection and testing.
Active case finding	<ul style="list-style-type: none"> Integrate COVID-19 into ongoing and planned active TB case finding initiatives. For example, this could include using existing TB mobile vans for joint screening, providing TB screening at mobile COVID-19 vaccination clinics, and screening in congregate settings such as slums. Community-level initiatives are also recommended to maximize outreach and awareness generation on how to minimize the risk of both TB and COVID-19 and signs and symptoms of infection.
Technical	
Diagnostic approach	<p>Integrated testing for TB and COVID-19 on available multiplex testing platforms would be ideal.</p> <p>Facilities without NAAT/multiplex platforms should strongly consider other options for the simultaneous testing of COVID-19 and TB such as:</p> <ul style="list-style-type: none"> On-site COVID-19 testing using rapid antigen tests with referral of TB samples to a laboratory. Chest X-ray (especially portable systems) potentially combined with computer-aided diagnosis (CAD) software, with careful consideration of infection control. <p>People with findings suggestive of TB and/or COVID-19 should be referred for confirmatory testing.</p>
Laboratory systems for COVID-19 and TB testing	<p>Consider which laboratory systems are available and most suitable for simultaneous testing of COVID-19 and TB in the health system. Available laboratory systems that can perform both COVID-19 and TB testing include:</p> <ul style="list-style-type: none"> Cepheid's GeneXpert® Systems Molbio Diagnostics' Truenat™ Roche cobas® 6800/8800 Systems Abbott m2000 RealTime System. <p>The first tool for the simultaneous testing of COVID-19 and TB in a single assay is in development by Molbio Diagnostics, India.</p>
Sample collection	<p>Validation of a single sample type for both TB and COVID-19 testing would be ideal to increase ease and uptake of simultaneous testing. Otherwise, samples for TB and COVID-19 should be collected in the same visit.</p> <p>The type of samples required will depend on the testing algorithm and types of tests employed. Testing for SARS-CoV-2 with NAAT or rapid antigen tests</p>

	typically requires nasopharyngeal/nasal/oral swabs, while testing for <i>Mycobacterium tuberculosis</i> typically requires a sputum sample.
Training	<p>Train COVID-19 programme staff to consider TB, and collect samples and conduct tests for TB on those suspected of having COVID-19, and vice versa.</p> <ul style="list-style-type: none"> • As this requires extra care and precaution, personnel must be appropriately trained in infection control methods and provided appropriate PPE. • Periodic trainings for providers in public and private sectors on updated scientific data and guidelines is also recommended.

Abbreviations: NAAT, nucleic acid amplification test; NGO, non-governmental organization; PPE, personal protective equipment; TB, tuberculosis.

Table: Considerations for the implementation of tuberculosis and COVID-19 simultaneous testing